HDAC inhibitors in liver cancer: which route to take? [electronic resource]
Producer: 20191213Description: 515-517 p. digitalISSN:- 1747-4132
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carcinoma, Hepatocellular -- drug therapy
- Clinical Decision-Making
- Disease Progression
- Epigenesis, Genetic -- drug effects
- Histone Deacetylase Inhibitors -- adverse effects
- Humans
- Liver Neoplasms -- drug therapy
- Patient Selection
- Treatment Outcome
No physical items for this record
Publication Type: Editorial
There are no comments on this title.
Log in to your account to post a comment.